MarketPulse
C

$CATX

5 articles found
4 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Rare Cancer Drug Market Surges 7.3% Annually as Novel Therapies Transform PCPG Treatment

PCPG cancer market projects 7.3% annual growth through 2036, valued at USD 300M in 2025, driven by novel drug classes and Novartis WELIREG leadership.
MRKNVSBHCCATXJAZZmarket growthradioligand therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Perspective Therapeutics, Inc.

Perspective Therapeutics Advances Rare Cancer Therapy With 43% Response Rate Data

Perspective Therapeutics reports 43% response rate for neuroendocrine tumor therapy with no serious safety issues, planning 2026 regulatory submissions.
CATXclinical trialcancer treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Perspective Therapeutics to Showcase Cancer Pipeline at Major Spring Biopharma Events

Perspective Therapeutics will present at two major investor conferences in April 2026, highlighting its alpha-emitting radiopharmaceutical pipeline for oncology.
CATXclinical trialscancer treatment
BenzingaBenzinga··Prnewswire

Biotech Pipeline Expands Arsenal Against Treatment-Resistant Cancers

Biotech firms advance treatment-resistant cancer therapies across multiple platforms, including oncolytic viruses and cellular immunotherapy, with several candidates achieving regulatory milestones and encouraging clinical data.
IBRXONCYNVCRCATXNUVBcolorectal cancerFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Perspective Therapeutics to Unveil 2025 Results and Clinical Pipeline Progress

Perspective Therapeutics will release 2025 financial results and clinical pipeline updates on March 16, highlighting progress in its cancer-targeting radiopharmaceutical programs.
CATXfinancial resultsclinical trials